Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia
Status:
Completed
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
All eligible Herpes Zoster patients will be randomized into two groups. Group 1 will be the
treatment group receiving Pregabalin 75 mg twice daily for 4 weeks in addition to other
routine treatment. Whereas, group 2 will be the control group receiving all routine treatment
similar to group 1 except Pregabalin. Instead control group will receive Placebo.
Phase:
Phase 4
Details
Lead Sponsor:
B.P. Koirala Institute of Health Sciences
Collaborators:
University Grants Commission University grants commission, Nepal (Funding source)